Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $35.82 Consensus Target Price from Analysts

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has earned a consensus recommendation of “Moderate Buy” from the eleven research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $36.00.

Several brokerages have recently weighed in on SNDX. JPMorgan Chase & Co. reduced their target price on shares of Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. UBS Group assumed coverage on shares of Syndax Pharmaceuticals in a research report on Thursday, October 24th. They issued a “buy” rating and a $37.00 price objective on the stock. The Goldman Sachs Group boosted their target price on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Barclays increased their price target on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the stock an “overweight” rating in a report on Thursday, August 15th. Finally, StockNews.com upgraded Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, November 7th.

Syndax Pharmaceuticals Stock Up 1.0 %

Syndax Pharmaceuticals stock opened at $16.79 on Friday. Syndax Pharmaceuticals has a 52-week low of $14.50 and a 52-week high of $25.34. The firm’s fifty day moving average is $18.99 and its 200 day moving average is $20.27. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -4.66 and a beta of 0.92.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.13) by $0.15. The company had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.16 million. During the same period in the previous year, the business earned ($0.73) earnings per share. On average, equities research analysts anticipate that Syndax Pharmaceuticals will post -3.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in shares of Syndax Pharmaceuticals by 13.6% in the 1st quarter. Vanguard Group Inc. now owns 4,926,984 shares of the company’s stock worth $117,262,000 after purchasing an additional 591,631 shares during the period. Sofinnova Investments Inc. lifted its holdings in Syndax Pharmaceuticals by 33.9% during the second quarter. Sofinnova Investments Inc. now owns 2,153,669 shares of the company’s stock worth $44,215,000 after buying an additional 545,129 shares during the period. First Turn Management LLC boosted its position in Syndax Pharmaceuticals by 85.4% during the 3rd quarter. First Turn Management LLC now owns 1,187,165 shares of the company’s stock valued at $22,853,000 after acquiring an additional 546,776 shares in the last quarter. StemPoint Capital LP increased its holdings in shares of Syndax Pharmaceuticals by 0.6% in the 1st quarter. StemPoint Capital LP now owns 1,100,988 shares of the company’s stock valued at $26,204,000 after acquiring an additional 6,494 shares during the period. Finally, Millennium Management LLC raised its position in shares of Syndax Pharmaceuticals by 56.3% in the 2nd quarter. Millennium Management LLC now owns 1,065,508 shares of the company’s stock worth $21,875,000 after acquiring an additional 383,634 shares in the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).